RNTX RNTX Clinical Operation Activities — Research And Development Expense

Other product segments

Similar metrics at other companies

MPLTClinical Trial — Research And Development Expense

$24.82M+1,180%

GERNResearch and clinical expenses — R&D

$13M-5.1%

STIMClinical Services — Research And Development Expense

$60K+17.6%

BCRXResearch, discovery and preclinical programs — Research and Development Expense (Excluding Acquired in Process Cost)

$3.97M+30.4%

OSTXChief Operating Decision Maker — Research And Development Expense

$7.35M+462%

MPLTPreclinical Program — Research And Development Expense

$5.52M-9.2%

Questions, answered.

What is RNTX's clinical operation activities — research and development expense?

RNTX (RNTX) reported clinical operation activities — research and development expense of $1.96M in Q1 2026.

How has RNTX's clinical operation activities — research and development expense changed year-over-year?

RNTX's clinical operation activities — research and development expense increased by 191.4% year-over-year, from $673K to $1.96M.

What is the long-term trend for RNTX's clinical operation activities — research and development expense?

Over 2 years (2023 to 2025), RNTX's clinical operation activities — research and development expense has grown at a 135.7% compound annual growth rate (CAGR), from $771K to $4.29M.

What does clinical operation activities — research and development expense mean?

This metric represents the total costs incurred by the company specifically for research and development activities within its clinical operations segment. It encompasses expenditures related to clinical trials, drug candidate development, and the scientific advancement of the company's therapeutic pipeline. Monitoring this expense provides insight into the company's investment intensity in bringing novel medical treatments through the regulatory and clinical testing phases.